Federated Hermes
TCRX icon

Federated Hermes’s TScan Therapeutics TCRX Stock Holding History

Federated Hermes’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.34K Sell
4,295
-694
-14% -$742 ﹤0.01% 1905
2025
Q4 		$4.99K Buy
4,989
+2,808
+129% +$4.06K ﹤0.01% 1893
2025
Q3 		$3.97K Hold
2,181
– – ﹤0.01% 1962
2025
Q2 		$3.16K Sell
2,181
-1
-0% -$1 ﹤0.01% 1922
2025
Q1 		$3.01K Buy
+2,182
New +$4.72K ﹤0.01% 1917
2024
Q2 		– Sell
-56
Closed -$445 – 2133
2024
Q1 		$445 Buy
+56
New +$352 ﹤0.01% 1990

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Federated Hermes's TCRX Position: Q1 2026 in Review

Federated Hermes reduced its TScan Therapeutics (TCRX) stake by 14% in Q1 2026, selling an estimated $742 and leaving 4,295 shares worth $4.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1905.

Federated Hermes first reported a position in TCRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $4.99K in Q4 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Federated Hermes held 4,295 shares of TScan Therapeutics worth $4.34K as of Q1 2026.
  • Federated Hermes sold 694 TScan Therapeutics shares in Q1 2026, an estimated $742.
  • TScan Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1905 holding.
  • Federated Hermes first reported a position in TScan Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Federated Hermes's TScan Therapeutics position peaked at $4.99K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.